BaseLaunch, a new life sciences accelerator in Basel, has been kicked off. Its mission: to bring the most promising healthcare projects and ventures to Europe’s leading life sciences hub.
https://european-biotechnology.com/wp-content/uploads/2024/04/BASELAUNCH_0155.jpg12781920Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-02-23 05:26:222017-02-23 05:26:22Kick off for BaseLaunch accelerator
While governments worldwide discuss to pay premiums to pharma companies offering novel antibiotics that fight multiresistant pathogens, Roche has extended its discovery deal with British Discuva Ltd.
Pfizer’s Cyprus Business Manager Kyriakos Mikellis has been re-elected for the next two years as president of the Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA).
https://european-biotechnology.com/wp-content/uploads/2024/04/kyriakos-mikellis.jpg393349h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2017-02-21 10:33:302017-02-21 10:33:30KEFEA: Re-elected president
Starting in May, Matthias Baumann will be new Chief Medical Officer of immunotherapy specialist Mologen AG. His primary goal will be preparing Mologen’s DNA cancer therapy lefitolimod for market launch.
Growth of the bioplastics market in the EU is being hampered by lack of political support. According to market analysis from nova-institute, production capacity for bio-based polymers in 2016 dropped by 6% compared to previous years.
Ex-Novartis Senior VP Judith Klimovsky has joined Copenhagen-based Genmab as Executive Vice President and Chief Development Officer. The appointment is meant to pave the way for the antibody specialist to grow into a global biotech company.
A combination therapy of Roche’s checkpoint inhibitor atezolizumab plus its VEGF blocker bevacizumab doubles median progression-free survival (PFS) compared to sunitinib, the standard care in renal cell carcinoma (RCC).
Basel-based BioMedPartners announes the first round of BioMedInvest III, its third equity venture capital fund at CHF75m. Up to 16 private Swiss, German and EU early-to-midstage ventures might be selected in the first closing by Q1/2018.
While GMO opponents are protesting, German Research Minister Johanna Wanka has recommended to rely on modern genetic engineering methods such as genome editing to develop the next generation of crops.
https://european-biotechnology.com/wp-content/uploads/2024/04/Wanke.jpg646969Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-02-16 09:43:262017-02-16 09:43:26Germany to allow GMOs without labelling
Raising €48m by the sale of 5.7 million shares at €8.50, French Inventiva S.A. is set to secure capital to further its late-stage products until H1/2019.
Kick off for BaseLaunch accelerator
Latest NewsBaseLaunch, a new life sciences accelerator in Basel, has been kicked off. Its mission: to bring the most promising healthcare projects and ventures to Europe’s leading life sciences hub.
Roche extends antibiotics collaboration
Latest NewsWhile governments worldwide discuss to pay premiums to pharma companies offering novel antibiotics that fight multiresistant pathogens, Roche has extended its discovery deal with British Discuva Ltd.
KEFEA: Re-elected president
AppointmentsMologen: Preparing for market launch
AppointmentsStarting in May, Matthias Baumann will be new Chief Medical Officer of immunotherapy specialist Mologen AG. His primary goal will be preparing Mologen’s DNA cancer therapy lefitolimod for market launch.
Bioplastics market growth drops
Latest NewsGrowth of the bioplastics market in the EU is being hampered by lack of political support. According to market analysis from nova-institute, production capacity for bio-based polymers in 2016 dropped by 6% compared to previous years.
Genmab: Pushing for growth
AppointmentsRoche combo doubles RCC survival vs sunitinib
Latest NewsA combination therapy of Roche’s checkpoint inhibitor atezolizumab plus its VEGF blocker bevacizumab doubles median progression-free survival (PFS) compared to sunitinib, the standard care in renal cell carcinoma (RCC).
BioMedPartners raise CHF75m fund
Latest NewsBasel-based BioMedPartners announes the first round of BioMedInvest III, its third equity venture capital fund at CHF75m. Up to 16 private Swiss, German and EU early-to-midstage ventures might be selected in the first closing by Q1/2018.
Germany to allow GMOs without labelling
Latest NewsWhile GMO opponents are protesting, German Research Minister Johanna Wanka has recommended to rely on modern genetic engineering methods such as genome editing to develop the next generation of crops.
Inventiva raises €48m in Euronext IPO
Latest NewsRaising €48m by the sale of 5.7 million shares at €8.50, French Inventiva S.A. is set to secure capital to further its late-stage products until H1/2019.